Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECIOUS: pertuzumab retreatment in previously pertuzumab-treated HER2-positive advanced breast cancer
jRCTs041180153Phase 3Completed
- Sponsor
- Japan Breast Cancer Research Group
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pertuzumab and trastuzumab in breast cancer (2 arms), sponsored by Japan Breast Cancer Research Group. Primary endpoint: Progression-free survival. Started Oct 2015; status: completed.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs041180153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180153.